ArticleCancers2022

Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study.

Motoo Nagane et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.